低风险妊娠 trofhoblastic瘤和复发率的巩固课程:一个MITO-9追溯研究
Raffaella Cioffi1, Robert Fruscio2, Giulia Sabetta1
1Department of Gynecological Oncology, IRCCS San Raffaele Hospital, Milan, Italy.
Gynecologic oncology
|April 3, 2025
概括
对于低风险的妊娠 trofhoblastic 瘤 (GTN),甲状腺素凝固疗程的数量不会影响复发率. 低FIGO分数的患者可以安全地接受两个整合疗程,优化治疗.
科学领域:
- 妇科 妇科 妇科 妇科
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 甲托雷克萨特 (MTX) 是对孕期热囊细胞瘤 (GTN) 的标准治疗方法.
- 巩固化疗疗程在达到负人类胆性腺激素 (hCG) 水平后进行,以防止复发.
- 对于低风险GTN的最佳整合课程数量仍然不清楚.
研究的目的:
- 评估MTX整合疗程数量与低风险GTN患者的复发率之间的关联.
- 为了确定更多的整合过程是否会降低GTN复发的风险.
- 确定可能从特定数量的巩固课程中受益的患者子组.
主要方法:
- 在意大利 (1981-2022) 接受一线MTX治疗的333名低风险GTN患者的回顾性分析.
- 排除仅用手术或不完整数据治疗的患者.
- 根据所接受的整合课程数量 (2,3 或 >3) 来评估复发率.
主要成果:
- 在224名患者中,41人 (17.4%) 接受了2次整合疗程,没有复发.
- 132名患者 (56.1%) 接受了3个疗程,复发率为2.2%,39名患者 (16.5%) 接受了>3个疗程,复发率为10.2%.
- 多变量分析表明,在FIGO分数为0-2.0的患者中,巩固疗程数量和复发之间没有显著的关系.
结论:
- 整合课程的数量不会显著影响低风险GTN的复发率.
- 具有FIGO分数为0,1和2的患者可以安全地接受两次整合疗程的治疗.
- 需要进一步的研究,以建立最佳的整合策略,为患者高FIGO得分.
关键词:
化学抗药性 化学抗药性是一种抗药性.巩固课程 巩固课程 巩固课程在FIGO得分中,FIGO得分是多少?低风险的妊娠 trofhoblastic 瘤.甲基甲酸二醇的使用方法复发率是什么意思?复发率是什么意思?更多相关视频
05:16Multiplexed Fluorescent Immunohistochemical Staining of Four Endometrial Immune Cell Types in Recurrent Miscarriage
Published on: August 4, 2021
3.3K
03:01Author Spotlight: A Reproductive Hysteroscopy Approach for Complete Endometrial Polyp Removal and Enhanced Endometrial Receptivity
Published on: August 2, 2024
550
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...